JP Morgan Chase’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

JP Morgan Chase’s Portfolio CALT Stock Details CALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-607	Closed	-$15.6K	–	7994
2023 Q4	$15.6K	Buy	607 +424	+232%	+$7.94K	﹤0.01%	6306
2023 Q3	$3.34K	Sell	183 -182	-50%	-$3.15K	﹤0.01%	6446
2023 Q2	$5.73K	Buy	+365	New	+$7.7K	﹤0.01%	6150
2023 Q1	–	Sell	-307	Closed	-$5K	–	7338
2022 Q4	$5K	Sell	307 -64	-17%	-$1.03K	﹤0.01%	6177
2022 Q3	$6K	Sell	371 -82	-18%	-$1.43K	﹤0.01%	6071
2022 Q2	$8K	Buy	453 +21	+5%	+$366	﹤0.01%	6086
2022 Q1	$8K	Sell	432 -96	-18%	-$1.93K	﹤0.01%	6261
2021 Q4	$13K	Buy	+528	New	+$10.6K	﹤0.01%	6292

Other funds holding CALT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

IIM

Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

JP Morgan Chase's CALT Position: Q1 2024 in Review

JP Morgan Chase sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q1 2024, closing a stake of 607 shares — an estimated $15.6K sold.

JP Morgan Chase first reported a position in CALT in Q4 2021 and held it in 8 quarters. The position peaked at $15.6K in Q4 2023. 19 funds tracked by Wall St. Rank hold CALT as of Q1 2024.

JP Morgan Chase reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q1 2024 after selling out during the quarter.
JP Morgan Chase sold 607 Calliditas Therapeutics AB American Depositary Shares shares in Q1 2024, an estimated $15.6K.
JP Morgan Chase first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q4 2021 and held it in 8 quarters.
JP Morgan Chase's Calliditas Therapeutics AB American Depositary Shares position peaked at $15.6K in Q4 2023.
19 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.